Early diagnostics Chip Diagnostics operates in exosome-based biomarker discovery for early disease diagnostics, presenting a sales angle for customers seeking innovative, non-invasive screening capabilities and early intervention tools.

AI driven platform The company combines hardware with data and AI informatics to rapidly analyze trillions of exosomes, offering a clear value proposition to pharma and diagnostics partners seeking scalable, high-throughput biomarker discovery and companion diagnostics.

Resource efficient Their workflow promises inexpensive and less resource-intensive processes compared to traditional methods, which can appeal to large biopharma and CROs aiming to reduce time to insight and overall study costs.

Small team agility With a lean team and early-stage revenue, Chip Diagnostics may be open to strategic collaborations, pilots, or co-development agreements to accelerate product validation and customer onboarding.

Market positioning Position against established players by highlighting rapid exosome fingerprinting and organ-specific insight as a differentiator, targeting partnerships with large diagnostics incumbents or instrument/agile biotech firms seeking innovative biomarkers.